In addition, GLP-1RAs are valuable in the treatment and prevention of diseases of the nervous and cardiovascular system, endocrine disorders, or metabolic diseases due to their neuroprotective, cardiovascular protective, and metabolic regulatory effects
Respuesta Rpida: La dosis de agonistas GLP-1 debe individualizarse segn el medicamento especfico, la indicacin clnica y la tolerabilidad del paciente, siguiendo esquemas de titulacin gradual supervisados mdicamente
The combined treatment of sCT and liraglutide, especially when administered in a stepwise manner, produced greater body weight loss, reduced adiposity and decreased plasma leptin levels compared to individual monotherapies and vehicle in DIO rats
The FDA has warned about unapproved GLP-1 products sold online and has noted concerns that illegally marketed products may be counterfeit, may contain incorrect or harmful ingredients, or may contain too little, too much, or none of the claimed active ingredients
doi: 10.1093/humupd/dmp008 142 MoranLJTassoneECBoyleJBrennanLHarrisonCLHirschbergALet al
The data is still early, but the signals are promising
